The FDA has approved two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease for patients 12 years of age and older, marking a significant step forward in the treatment of the disease.
The FDA has approved two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease for patients 12 years of age and older, marking a significant step forward in the treatment of the disease.
